Corey Hopkins Archives
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Feb. 3, 2012—Vanderbilt researcher and Gabon, Africa, native is working to discover ways to kill malaria-spreading mosquitoes.
Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.